Cisplatin-induced nephrotoxicity is a crucial concern in cancer patients, limiting the dose and duration of cisplatin therapy. Several mechanisms contribute to cisplatin nephrotoxicity, including oxidative stress, inflammation, and mitochondrial dysfunction. SGLT2 inhibitors have emerged as a promising therapeutic option for various renal disorders due to their ability to restore renal homeostasis and mitigate renal injury
Implication for health policy/practice/research/medical education:
Cisplatin is a broadly administered chemotherapeutic compound for the treatment of several solid tumors; though, its use is frequently limited due to the development of nephrotoxicity. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs utilized to treat type 2 diabetes by inhibiting the SGLT2 accountable for glucose reabsorption in the kidneys. These inhibitors have also shown promise in improving renal function following administration of cisplatin, a commonly used chemotherapeutic drug that can cause kidney damage.
Please cite this paper as: Keshtgar P, Mahmoodnia L, Karamian S. Possible amelioration impact of sodium-glucose cotransporter 2 inhibitors on cisplatin-induced renal toxicity; a mini-review on recent findings. J Renal Inj Prev. 2023; 12(4): e32245. doi: 10.34172/jrip.2023.32245.